Tag: Clinical Research Pathways

Expert on #FDA’s #Expanded Access program: Cost can be a barrier to critically ill patients, healthcare providers, and others seeking to try experimental treatments as a last resort. Dr. Marjorie A. Speers available to comment or participate in inter

sarah JonasExpert Pitch

Costs related to the expanded access procedure under which critically ill patients can  try experimental drugs, biologics, and medical devices are often overlooked. These costs, according to Clinical Research Pathways Executive Director Marjorie A. Speers, Ph.D. can become a barrier for patients,…